Highland Venture Capital

Investing throughout Scotland in emerging business


insignia HCV first invested in Syntropharma in 2008 along with another syndicate and The Scottish Co-Investment fund. Since that time the syndicate has continued to support the company with additional funding rounds and resources.

After a very challenging but fruitful 2013 when excellent progress was made in a number of key strategic commercial areas, 2014 looks to be an interesting year with the company’s lead compound now having distribution agreements for Europe, America and South America. The Product is also expected to receive regulatory approval in South America during the first half of 2014.

The company’s second compound is in the process of having a marketing agreement signed. The company is also seeking funding to take a third compound to manufacture and on to testing.


amt-logo The company is a global leader in the use of microwaves to heat and condition liquids, suspensions and semi solids.  Microwaves offer a unique method of delivering energy into certain materials and despite being used extensively in many areas, their use in liquid systems has largely remained limited to small devices and laboratory scale equipment.

AMT has overcome the technical barriers which have restricted this development and has developed a unique and patented system of delivering microwave energy deep into liquids on a continuous basis and on an industrial scale.When HVC initially invested in the company, the aim was to develop a machine that would sterilise the blood waste from abattoirs. The product worked as designed and is capable of treating any potentially bio hazardous material which needs to be sterilised prior to final treatment or disposal. However the market has not yet proven itself ready to accept this new and disruptive technology.

Since then HVC has supported the company with additional funding rounds to develop the technology for use in the food and drinks industry. The company has worked with several academic institutions, including Queen Margaret University, to obtain accreditation for the technology. It has been particularly successful in the fruit juice market, where it has proved that it can pasteurise juice and significantly extend its shelf-life whilst reducing the vitamin damage and maintaining taste and colour.

The most recent funding round was completed in November 2013 and part of its purpose was to strengthen the senior management team.  Earlier in 2013 the company was pleased to welcome the appointment of Dr. Derek Shepherd as Chairman and in January 2014 the appointment of Stephen Roe as Chief Executive Officer.


picture-lamellar Lamellar Biomedical Ltd is a biotechnology company established to research, develop and commercialise the role of lamellasomes ® in serious hereditary disorders.


Actual Analytics use cutting-edge video analysis technology to automatically analyse behaviour – a crucial step in the development of new drugs treating diseases of the Central Nervous System (CNS), such as Alzheimer’s and Parkinson’s. Disorders of the nervous system affect 1 in 3 people during their lives, account for the largest single burden on the NHS and are often long-term disabling illnesses for the patient, their friends and family. At an estimated cost of over US$800m to take a new drug to market, Actual Analytics’ product will help customers cut costs and remove a significant bottleneck in the drug discovery pipeline.


Design LED Products Ltd specialises in the design, development, and licensed manufacture of segmented light displays using its patented ‘printed light-guide’ technology with standard Light Emitting Diode (LED) components. The resultant technology platform provides significant competitive advantage via thin, low cost, flexible and high energy efficient backlighting solutions in a fast growing global LED market pipeline.


 carbonblack At the age of 14 Andrew Slorance fell from a tree and broke his back. Throughout a twenty–year career in television Andrew‘s aim to create the perfect chair grew. Andrew resigned his job and dedicated himself to making Carbon Black a reality.

It took six years for Andrew to fund and develop Carbon Black but today his vision is a reality. For Andrew the Carbon Black chair is just the beginning of a range of highly advanced products that will come from the Carbon Black brand.

In 2012 HVC invested in the company and have support Andrew in his aim to produce the perfect wheelchair. This support has come not only in the form of some additional funding, but in the constant help and advice from HVC members.

By the end of 2013 the Carbon Black wheelchair is a reality, with orders taken and deliveries starting in January 2014.


 insignia Insignia Technologies, the smart packaging company, today announced an £865,000 investment led by Equity Gap along with Highland Venture Capital, the Scottish Investment Bank, Strathclyde University and a number of private investors.

Insignia Technologies has developed a smart food label that changes colour over time to show how long a packet of food has been open. This simple concept using patented smart pigment technology has clear benefits for shoppers, retailers, and food producers. Removing the confusion around how long a pack has been opened it reduces unnecessary food waste while restoring consumer confidence in certain food categories which in turn drives repeat purchase and increased sales.


 cardioprecision Cardioprecision Ltd is an award-winning company, developing high quality medical devices for minimally invasive cardiovascular surgery. Currently its primary focus is on medical instrumentation dedicated to minimal access aortic valve replacement (AVR).

Open heart AVR is the gold standard surgical treatment for advanced aortic calve disease. However, it requires splitting the breastbone (sternotomy). This inflicts significant patient trauma, requires extensive recuperation and may result in life-threatening complications. Therefore, there is a pressing need for innovation that allows surgical AVR to be performed minimally invasively.

CadrioPrecision Ltd is developing a medical device to allow the surgeon to perform AVR through a small incision without sternotomy. This minimally invasive technology will cause less pain and lead to earlier mobilisation and recovery from surgery. It will not only improve the patients quality of life but also provide substantial economic savings to health service providers. This will be achieved through value-creating reductions in operating time, blood loss, transfusion requirements, infection rates, intensive care utilisation and hospital stay.